VJOncology is committed to improving our service to you

ESMO 2019 | One to watch: KEYNOTE-866, perioperative pembro with neoadjuvant chemo in MIBC

VJOncology is committed to improving our service to you

Arlene Siefker-Radtke

Speaking from the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain, Arlene Siefker-Radtke, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the ongoing phase 3 KEYNOTE-866 study (NCT03924856). This trial is investigating perioperative pembrolizumab in combination with neoadjuvant chemotherapy in cisplatin-eligible patients wth muscle-invasive bladder cancer.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter